SHL Telemedicine Ltd
SHLTN
ISIN IL0010855885 / Valor 1128957
SHL Telemedicine Ltd
UMushroom community rating:
About company
SHL Telemedicine Ltd is an Israel-based provider of remote patient monitoring and telehealth solutions that integrates wearable devices and sensors with cloud software and 24/7 clinical call-center services to support elderly and chronically ill patients. The company supplies medical alert systems and mobile monitoring units, operates clinical and care‑management services that enable remote triage, medication oversight and early intervention, and provides analytics and reporting to healthcare partners. SHL sells hardware and subscription-based monitoring and care contracts to payers, providers, employers and direct consumers, positioning its revenue around recurring service agreements and device sales delivered through partnerships and regional operations.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (27.07.2026):
SHL Telemedicine Ltd — Q4 2024 / Full-year 2024: SHL reported stable full‑year revenue of USD 57 million for 2024 but recorded a materially larger net loss of USD 28 million (vs. USD 7 million in 2023), driven mainly by one‑time non‑cash write‑downs in its German operations; operational performance (Adjusted EBITDA) was broadly stable once the non‑recurring items are excluded.
Revenue
Total revenue for FY2024 was USD 57 million, roughly flat versus 2023. Geographic mix: Israel ~77% of revenues, Germany ~22%, remainder from the US.
Net loss and one‑time charges
Net loss widened to USD 28 million in 2024 from USD 7 million in 2023. The primary driver was USD 20 million recorded in “other expenses,” largely a one‑time write‑off of intangible assets (principally goodwill) related to the German business.
Adjusted EBITDA and operational performance
Adjusted EBITDA (which excludes the one‑time other expenses) remained relatively stable at about USD 1 million in 2024 (USD 2 million in 2023), indicating day‑to‑day operations were not substantially different year‑over‑year when non‑recurring costs are ignored.
Cash impact
Management notes that approximately 86% of the USD 20 million one‑time charge was non‑cash, limiting the immediate impact on cash flow and the company’s stated ability to execute its business plans.
Israel operations
Israeli operations showed revenue growth and improved profitability in 2024, driven by the B2B Mediton business through economies of scale. SHL announced intent to acquire the remaining 30% of Mediton for NIS 31.1 million (≈USD 8.4–8.5m); as of the report date the deal was not yet closed.
Germany operations
German revenue declined (~USD 1.4 million lower) and operational profit remained negative. The goodwill/intangible write‑off reflects market trends and the need for further investment (notably an updated IT service platform) to restore efficiency and profitability.
US strategy
In the US, SHL is pursuing both B2B (partners such as CVS and DOC GO) and D2C channels, emphasizing SmartHeart® ECG technology and remote cardiologist review to scale services.
Corporate actions and governance
2024 included major leadership changes (new board, new CEO appointed in 2024). Post‑year events: SHL announced voluntary delisting from Nasdaq in March 2025 (ADSs delisted March 31, 2025) while ordinary shares continue trading on the SIX Swiss Exchange; a new CFO appointment was announced effective March 1, 2025.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
37 M
Market cap (USD)
12,654
Daily traded volume (Shares)
2.67 / 2.43
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Janin Sägesser
EQUITIES OF THE SAME SECTOR
